p35 HEMIZYGOSITY ACTIVATES Akt BUT DOES NOT IMPROVE MOTOR FUNCTION IN THE YAC128 MOUSE MODEL OF HUNTINGTON'S DISEASE

被引:5
|
作者
Park, Kevin H. J. [1 ]
Franciosi, Sonia [1 ]
Parrant, Kristina [1 ,3 ]
Lu, Ge [1 ]
Leavitt, Blair R. [1 ,2 ]
机构
[1] Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada
[2] Univ British Columbia, Dept Med, Div Neurol, Vancouver, BC V5Z 4H4, Canada
[3] Ctr Drug Res & Dev, Vancouver, BC V6T 1Z3, Canada
关键词
Huntington's disease; YAC128 mouse model; P35; P25; transgenic mice; mutant huntingtin; CYCLIN-DEPENDENT KINASE-5; NEURONAL CDK5 ACTIVATOR; NMDA RECEPTOR FUNCTION; MEDIATED EXCITOTOXICITY; PHOSPHORYLATION; PROTEIN; TOXICITY; CLEAVAGE; MICE; P25;
D O I
10.1016/j.neuroscience.2017.03.051
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huntington's disease (HD) is a hereditary neurodegenerative disorder resulting from N-terminal polyglutamine expansion in the huntingtin protein. A relatively selective and early loss of medium spiny neurons in the striatum Is a hallmark of HD neuropathology. Although the exact mechanism of mutant huntingtin-mediated neurodegeneration is unclear, recent evidence suggests that NMDA-receptor-mediated excitotoxicity Is involved. Our previously published findings show that decreasing levels of the cdk5 activators, p35 and p25, reduces NMDA receptor mediated excitotoxicity in striatal neurons in vivo. In this study we directly examined the effect of reducing levels of p35 and p25 in the context of mutant huntingtin toxicity, using the B6 YAC128 mouse model of HD. Our findings demonstrate that deletion of a single allele of p35 in the B6 YAC128 mice results in an upregulation of Akt activity, and increases phosphorylation of mutant huntingtin at Ser421. Longitudinal behavioral analysis showed that this 50% reduction in p35 and p25 levels did not improve accelerating Rotarod performance in these YAC128 mice. However, a complete deletion of p35 normalized the accelerating Rotarod performance relative to their non-transgenic littermates at four months of age. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:79 / 87
页数:9
相关论文
共 50 条
  • [1] Oxidative metabolism in YAC128 mouse model of Huntington's disease
    Hamilton, James
    Pellman, Jessica J.
    Brustovetsky, Tatiana
    Harris, Robert A.
    Brustovetsky, Nickolay
    HUMAN MOLECULAR GENETICS, 2015, 24 (17) : 4862 - 4878
  • [2] Neuroinflammation in the YAC128 transgenic mouse model of Huntington's disease
    Connolly, C.
    Thiele, J.
    Beck, J.
    Lefroy, C.
    Hill, A.
    Leavitt, B. R.
    MOVEMENT DISORDERS, 2012, 27 : S58 - S58
  • [3] Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease
    Van Raamsdonk, JM
    Pearson, J
    Slow, EJ
    Hossain, SM
    Leavitt, BR
    Hayden, MR
    JOURNAL OF NEUROSCIENCE, 2005, 25 (16): : 4169 - 4180
  • [4] TREATMENT WITH ARIMOCLOMOL DOES NOT LEAD TO RESCUE OF MOTOR OR STRIATAL DEFICITS IN THE YAC128 MOUSE MODEL OF HUNTINGTON'S DISEASE
    Pouladi, M. A.
    Carroll, J.
    Santos, R. Dar
    Bertram, L.
    Hayden, M. R.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2010, 81 : A14 - A14
  • [5] EVALUATION OF PRIDOPIDINE IN THE TRANSGENIC YAC128 MOUSE MODEL OF HUNTINGTON'S DISEASE
    Miralles, Marta Garcia
    Tan, Liang Juin
    Lim, Madeline
    Geva, Michal
    Hayden, Michael R.
    Pouladi, Mahmoud A.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2016, 87 : A92 - A92
  • [6] Striosome-matrix pathology and motor deficits in the YAC128 mouse model of Huntington's disease
    Lawhorn, Collene
    Smith, Diane M.
    Brown, Lucy L.
    NEUROBIOLOGY OF DISEASE, 2008, 32 (03) : 471 - 478
  • [7] Selective cognitive impairment in the YAC128 Huntington's disease mouse
    Brooks, Simon P.
    Janghra, Nari
    Higgs, Gemma V.
    Bayram-Weston, Zubeyde
    Heuer, Andreas
    Jones, Lesley
    Dunnett, Stephen B.
    BRAIN RESEARCH BULLETIN, 2012, 88 (2-3) : 121 - 129
  • [8] Automated deformation analysis in the YAC128 Huntington disease mouse model
    Lerch, Jason P.
    Carroll, Jeffrey B.
    Spring, Shoshana
    Bertram, Lisa N.
    Schwab, Claudia
    Hayden, Michael R.
    Henkelman, R. Mark
    NEUROIMAGE, 2008, 39 (01) : 32 - 39
  • [9] Cystamine treatment is neuroprotective in the YAC128 mouse model of Huntington disease
    Van Raamsdonk, JM
    Pearson, J
    Bailey, CDC
    Rogers, DA
    Johnson, GVW
    Hayden, MR
    Leavitt, BR
    JOURNAL OF NEUROCHEMISTRY, 2005, 95 (01) : 210 - 220
  • [10] Evaluation of pridopidine in the transgenic YAC128 mouse model of Huntington disease
    Garcia-Miralles, M.
    Yosuf, N. A. B. M.
    Tan, J. Y.
    Kusko, R.
    Tan, L. J.
    Xu, X.
    Orbach, A.
    Geva, M.
    Hayden, M. R.
    Pouladi, M. A.
    JOURNAL OF NEUROCHEMISTRY, 2017, 142 : 219 - 219